308-nm Excimer laser treatment of palmoplantar psoriasis.

J Cosmet Laser Ther

Skin Laser & Surgery Specialists of New York and New Jersey, New York, NY, USA.

Published: April 2011

Psoriasis is a chronic inflammatory condition affecting 1-3% of the population. The incidence of palmoplantar involvement has been estimated to be between 2.8% and 40.9%. Significant psychosocial distress and difficulty performing activities of daily living can result. Treatment is often challenging. Traditional treatments include topical steroids, anthralin, calcipotriene, PUVA, methotrexate, cyclosporine, retinoids and biologics. In this case series, we report our success with the 308-nm excimer laser in the treatment of palmoplantar psoriasis.

Download full-text PDF

Source
http://dx.doi.org/10.3109/14764172.2011.564769DOI Listing

Publication Analysis

Top Keywords

308-nm excimer
8
excimer laser
8
laser treatment
8
treatment palmoplantar
8
palmoplantar psoriasis
8
psoriasis psoriasis
4
psoriasis chronic
4
chronic inflammatory
4
inflammatory condition
4
condition 1-3%
4

Similar Publications

One of the most frequently impacted locations by psoriasis is the scalp. It is seen in about 80% of psoriasis cases worldwide, and its treatment is challenging. To compare the efficacy and safety of excimer light versus topical methotrexate (MTX) 1% hydrogel in treatment of scalp psoriasis.

View Article and Find Full Text PDF

Patients with progressing facial vitiligo who had been treated with upadacitinib, 308 nm excimer light and upadacitinib combined with 308 nm excimer light were selected for retrospective analysis and comparison of their efficacy and safety. Efficacy was evaluated using the Vitiligo Area Severity Index (VASI) and Dermatology Life Quality Index (DLQI) at baseline, after 8 weeks, and after 20 weeks. The progression of skin lesions was monitored through reflectance confocal microscopy (RCM), while adverse reactions were documented.

View Article and Find Full Text PDF

Background: Previous studies have proven that 308-nm light-emitting diode(308-nm LED)and 308-nm excimer lamp(308-nm MEL) are effective in treating vitiligo, but there is a lack of comparison of their efficacy for facial lesions.

Objective: To evaluate and contrast the treatment success rates of 308-nm LED versus 308-nm excimer lamp in managing facial lesions among patients suffering from stable non-segmental vitiligo.

Methods: The enrolled 119 patients with 145 lesions were randomly assigned to receive 308-nm LED or 308-nm MEL for two months.

View Article and Find Full Text PDF

Background: Vitiligo is a clinically prevalent acquired skin disorder characterized by depigmentation. Currently, the therapeutic options for vitiligo are restricted, and numerous issues exist, such as a prolonged treatment course, unsatisfactory therapeutic efficacy, adverse reactions, and a high propensity for recurrence after treatment cessation.

Aim: To assess the safety and efficacy of combined treatment involving oral tofacitinib citrate (TC) and a 308-nm excimer laser (EL), with the aim of discovering a rapid and effective treatment approach to minimize the side effects of various drugs.

View Article and Find Full Text PDF

Background: A 308 nm excimer light is an effective treatment for vitiligo, with fewer treatment times, rapid obvious effects, relatively complete pigment recovery, good patient compliance, and safe and effective treatment for children. The disadvantage of this treatment is that some patients have a plateau during which the skin lesion reduction rate slows down or stalls after multiple treatments.

Methods: Treatment data were collected from all vitiligo patients in the Dermatology Department, distinguishing between those who underwent 308 nm excimer light treatment alone and those who received a combination of 308 nm excimer light and 2940 erbium laser treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!